Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence.
about
Mapping track density changes in nigrostriatal and extranigral pathways in Parkinson's diseaseMultimodal MRI Evaluation of the MitoPark Mouse Model of Parkinson's DiseaseIs R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.A review of structural magnetic resonance neuroimaging.A review of the use of magnetic resonance imaging in Parkinson's disease.Iron in chronic brain disorders: imaging and neurotherapeutic implications.Brain imaging and networks in restless legs syndrome.Quantitative assessment of susceptibility-weighted imaging processing methodsPost translational changes to α-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson's disease.Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseasesMagnetic resonance imaging measurement of iron overload.Voxel-based statistical analysis of fractional anisotropy and mean diffusivity in patients with unilateral temporal lobe epilepsy of unknown cause.Serum cholesterol and nigrostriatal R2* values in Parkinson's disease.Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies.Iron homeostasis and the inflammatory responseInsulin resistance impairs nigrostriatal dopamine functionBiomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeuticsMRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patientsPotential of Diffusion Tensor Imaging and Relaxometry for the Detection of Specific Pathological Alterations in Parkinson's Disease (PD)A comparison of MRI tissue relaxometry and ROI methods used to determine regional brain iron concentrations in restless legs syndrome.Caveosomal oxidative stress causes Src-p21ras activation and lysine 63 TRAF6 protein polyubiquitination in iron-induced M1 hepatic macrophage activation.Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.Imaging nigral pathology and clinical progression in Parkinson's disease.Lateral Asymmetry and Spatial Difference of Iron Deposition in the Substantia Nigra of Patients with Parkinson Disease Measured with Quantitative Susceptibility MappingEffects of hemochromatosis and transferrin gene mutations on peripheral iron dyshomeostasis in mild cognitive impairment and Alzheimer's and Parkinson's diseases.Susceptibility-weighted MRI of extrapyramidal brain structures in Parkinsonian disorders.Neuromelanin Imaging and Dopaminergic Loss in Parkinson's DiseaseBrain iron deficiency in idiopathic restless legs syndrome measured by quantitative magnetic susceptibility at 7 tesla.MRI estimates of brain iron concentration in normal aging: comparison of field-dependent (FDRI) and phase (SWI) methods.Meta-analysis of brain iron levels of Parkinson's disease patients determined by postmortem and MRI measurements.Quantitative susceptibility mapping of the midbrain in Parkinson's diseaseDifferences between conventional and nonconventional MRI techniques in Parkinson's disease.Metabolic reprogramming and cell fate regulation in alcoholic liver disease.Regionally progressive accumulation of iron in Parkinson's disease as measured by quantitative susceptibility mapping.Iron causes interactions of TAK1, p21ras, and phosphatidylinositol 3-kinase in caveolae to activate IkappaB kinase in hepatic macrophages.Determination of brain iron content in patients with Parkinson's disease using magnetic susceptibility imaging.On the lorentzian versus Gaussian character of time-domain spin-echo signals from the brain as sampled by means of gradient-echoes: Implications for quantitative transverse relaxation studiesNovel Pattern of Iron Deposition in the Fascicula Nigrale in Patients with Parkinson's Disease: A Pilot StudyQuantitative assessment of subcortical atrophy and iron content in progressive supranuclear palsy and parkinsonian variant of multiple system atrophy.The effects of prenatal methylmercury exposure on trace element and antioxidant levels in rats following 6-hydroxydopamine-induced neuronal insult.
P2860
Q24040262-3BC6062D-9474-4DAE-85D1-629BE0FBC191Q27316725-A159DC1E-076D-45C0-A680-2434537E2D8DQ30457611-B516251D-5E78-4749-898A-5964449510CDQ30495444-A46B3439-D481-4A6F-9210-CFAE2FA3196CQ30835548-8E005B0A-4BE3-4F31-A6BF-14359A77CA37Q31117154-0A83D9D6-4D9E-4C81-8441-727585A1670AQ31142064-A3A908E6-A317-4F88-B16F-C8D168D6A60AQ33763843-D478BC51-69A2-4BA7-97DA-AC387B6C18F7Q33776138-AB46D64C-5230-4AFD-8949-950ED8E24B22Q33909042-97D63194-5233-4B8C-8F89-1E2FAA0A7850Q33944366-DD1C5FBD-FE0A-4E04-BE6B-6089D1776773Q34115501-CB740876-67F0-4D38-82B1-EE79B3B4E73CQ34243731-0ED6BB4D-379A-4FBC-B639-7BEE8EFD0D9FQ34372099-5BCE8489-03B7-4D87-B849-22DFDC2FA28CQ35024676-39B1933A-E80C-400A-90FC-A6CDF62B6554Q35202338-6AF3D7D5-63F3-4264-B992-0B350A07C7B3Q35649302-643C9812-5500-405E-9156-7EFDA612CC63Q35848072-C10CB6CB-A15A-476D-A935-CE5120262B72Q35880556-74F37B34-637D-4B39-8FD7-4D3D2C9A5BB6Q35918844-FB09C37A-8E69-4181-AB96-77BEAC195B61Q36234784-9620C93B-71F6-47BF-B904-169DC7B954BBQ36374541-D2D2DDC6-0BF9-4762-B682-01B31FE95A5CQ36434577-1BC9A645-70CF-42FF-B698-C68F4A85C3CDQ36902028-BD884897-DE1A-479E-B574-82859DB23F1CQ37068758-A3259975-365F-49A1-BCC7-7D08A922601EQ37077841-95193C6B-3185-49EB-88B7-C7D527ED96FEQ37192855-6C173364-CEA4-49F4-AEBD-5912AF6FE488Q37193370-1CDA1D08-9A56-4607-BE9B-8EFCEA5E12CDQ37370641-FE8BC77E-3B0E-4E6E-BB12-1E4F8B459376Q37402514-738EEB75-15B5-4163-9114-7DB5778476C4Q37650486-2783D01E-D0D2-4B83-A1C6-A485362A5FEBQ38152514-FBAB245B-9E5C-41D4-ADD6-A13A49133537Q38387716-625BC3BE-A7C5-4C7B-BE44-25AC694D3D4FQ40016191-6EAE9A6E-9686-4710-8ADE-66604A18AC59Q40195592-5FB17A77-D560-47C8-900B-CDEA78480D7EQ41350914-65D771BE-1665-483E-A4F4-0EAC2AE9B42EQ41777125-633664F6-2621-4986-BAB2-40100D8AC303Q42416323-B1244D6C-28DC-416D-ACC1-C2879F1C2187Q44649355-2017A7E1-0038-49F9-A11C-00FF97E1C23AQ45324691-413BAB03-75A5-4F0E-B3CB-B48ED03A5914
P2860
Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Brain iron deposition in Parki ...... E magnetic resonance sequence.
@en
Brain iron deposition in Parki ...... E magnetic resonance sequence.
@nl
type
label
Brain iron deposition in Parki ...... E magnetic resonance sequence.
@en
Brain iron deposition in Parki ...... E magnetic resonance sequence.
@nl
prefLabel
Brain iron deposition in Parki ...... E magnetic resonance sequence.
@en
Brain iron deposition in Parki ...... E magnetic resonance sequence.
@nl
P2093
P356
P1433
P1476
Brain iron deposition in Parki ...... E magnetic resonance sequence.
@en
P2093
Griffiths PD
Grünewald RA
P304
P356
10.1093/BRAIN/123.12.2423
P407
P478
P577
2000-12-01T00:00:00Z